TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06204783

Intervention type: OTHER
Intervention: Pressure volume (PV) loop measurement
Description: Pressure volume (PV) loop measurement using a conductance catheter

Intervention type: OTHER
Intervention: Pressure volume (PV) loop measurement
Description: Pressure volume (PV) loop measurement using a conductance catheter

Intervention type: OTHER
Intervention: Pressure volume (PV) loop measurement
Description: Pressure volume (PV) loop measurement using a conductance catheter
Study: NCT06250270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein or placebo
Description: casein protein (30g) or placebo (maltodextrin, 30g)
Study: NCT06446388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg, intravenous infusion,D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg, intravenous infusion,D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg, intravenous infusion,D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg, intravenous infusion,D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg, intravenous infusion,D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Standard chemotherapy recommended by guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Standard chemotherapy recommended by guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Standard chemotherapy recommended by guidelines.
Study: NCT04823507

Intervention type: DEVICE
Intervention: BIOFLEX DUO+
Description: * Data scores will be collected for patients who initially underwent the Workplace Post-Injury 1 test of the ImPACT® test system prior to PBM treatment.~* Patients were treated with photobiomodulation using the BIOFLEX® DUO+ system that utilized a 180 bulb Light Emitting Diode (LED) array followed by laser probes. Both delivery methods were applied to the cervical spine and the cranium, and both entailed the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided three times per week on alternating days with weekends off for 4 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for treatment of the cervical spine.~* Data scores will be collected for a second ImPACT® test using the Workplace Post-Injury 2 test.~* Results of the Post-Injury 1 test and the Post-Injury 2 test will be compared.
Study: NCT06384794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sperm capacitation through the ZyMōt®Sperm Separation Device®
Description: This chip based on microfluidic properties will help us to separate and recover the semen sample with improved sperm quality. It is composed of two microwells, one initial and one final, and a porous membrane through which the sample will be filtered and the capacitated spermatozoa with better motility will be selected. Syringe 850µL of the initial seminal sample into the first well and 750µL of seminal wash medium into the second well. The device is incubated at 37°C for up to 30 minutes. During this incubation, the sample will travel by microfluidic properties from the first well through the porous membrane to the second well. This membrane will filter those spermatozoa with a higher motility. Thus, at the end of the established incubation time, the medium with the selected spermatozoa from the second well (final well) will be collected with a syringe. After this, the sample will be processed and ready for the following procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Swim-up
Description: The swim-up is a sperm capacitation technique in which the motile spermatozoa of the seminal sample, after centrifugation and incubation, move to the upper part of the medium. In this way, spermatozoa with good progressive motility will remain in the supernatant.
Study: NCT04945018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-001 CS
Description: Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-001 CS
Description: Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-001-D needle, HS-001-D Adaptor
Description: Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-001-D needle, HS-001-D Adaptor
Description: Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors
Study: NCT06469619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Listening to music of one's choice one hour daily.
Study: NCT03810573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB1
Description: rhNELL-1/DBX

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB1
Description: rhNELL-1/DBX
Study: NCT05158140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V110
Description: Single intramuscular (IM) dose of 0.5 mL V110, a pneumococcal polysaccharide vaccine (PCV), containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V110
Description: Single intramuscular (IM) dose of 0.5 mL V110, a pneumococcal polysaccharide vaccine (PCV), containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
Study: NCT04936542

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AboBoNT-A
Description: AbobotulinumtoxinA for injection: 500 Unit vial. Dose: 900 Units (3.6 mL)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AboBoNT-A
Description: AbobotulinumtoxinA for injection: 500 Unit vial. Dose: 900 Units (3.6 mL)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: OnaBoNT-A
Description: OnabotulinumtoxinA for injection: 200 Unit vial. Dose: 360 Units (3.6 mL)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: OnaBoNT-A
Description: OnabotulinumtoxinA for injection: 200 Unit vial. Dose: 360 Units (3.6 mL)
Study: NCT06454604

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meta Quest 3 VR Headset with noise cancelling headphones
Description: Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meta Quest 3 VR Headset with noise cancelling headphones
Description: Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.
Study: NCT04877483

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: complete blood count (CBC)
Description: Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: complete blood count (CBC)
Description: Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: complete blood count (CBC)
Description: Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SF-36(36-Item Short Form Survey )
Description: Group GB20 and Group GB20 plus BL2 will take the SF-36 test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SF-36(36-Item Short Form Survey )
Description: Group GB20 and Group GB20 plus BL2 will take the SF-36 test.
Study: NCT05057507

Intervention type: DIAGNOSTIC_TEST
Intervention: Atrial cardiac magnetic resonance imaging
Description: To include assessment of atrial size, shape, function, fibrosis and fat

Intervention type: DIAGNOSTIC_TEST
Intervention: Atrial electro-anatomic mapping
Description: To include assessment of atrial voltage and local activation time

Intervention type: OTHER
Intervention: Atrial fibrillation symptom questionnaire
Description: To include assessment of atrial fibrillation symptoms and quality of life

Intervention type: DIAGNOSTIC_TEST
Intervention: Patch-based 2 week ambulatory monitor
Description: To assess atrial fibrillation burden post-ablation
Study: NCT06454604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meta Quest 3 VR Headset with noise cancelling headphones
Description: Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.
Study: NCT04931576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no drainage tube applied
Description: No drainage tube implacement after TOETVA
Study: NCT05093621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Standard of care diuretic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Torsemide
Description: Standard of care diuretic
Study: NCT06173375

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cologuard
Description: Multi-target stool DNA test for colorectal cancer screening implemented by Exact Sciences. Cologuard has 94% sensitivity and 87% specificity to detect colorectal cancer.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Immunochemical Test
Description: Stool blood test for colorectal cancer screening. FIT has 75% sensitivity and 90% specificity to detect colorectal cancer.
Study: NCT04877483

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SF-36(36-Item Short Form Survey )
Description: Group GB20 and Group GB20 plus BL2 will take the SF-36 test.
Study: NCT05236296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EASE-CG
Description: EASE-CG is an adapted brief psychotherapeutic intervention with relational support and trauma-based cognitive behavioral therapy (CBT) components.
Study: NCT05084014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Stripping
Description: The deep longitudinal stripping can be applied on adhesions and knots in muscles. The lengthening stokes are parallel to muscle fiber and applied in an oblique direction with the help of the thumbs of hands/ elbow/ knuckles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kneading
Description: kneading lifts the muscle in circular movements with the help of the hands. It lifted, rolled, and squeezed muscle
Study: NCT05397899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal hypopressive Exercises (AHE)
Description: Active and specific Therapeutic exercises will be used to treat postpartum low back pain in this study. AHE consisted of exhaling to their expiratory reserve volume, then holding their breath (apnea), and expanding their rib cage, to draw their abdominal wall inward and cranially without inhalation. Each exercise will have a specific frequency, intensity, and duration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General exercises
Description: General exercises are therapeutic exercises for core muscles for the treatment of postpartum low back pain.
Study: NCT05757102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: FF/UMEC/VI will be administered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELLIPTA
Description: FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/VI
Description: FF/VI will be administered.
Study: NCT05166564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Protein Enriched Mediterranean Diet (PROMED) Intervention
Description: Researchers will provide individually tailored dietary advice and written materials to encourage 'a little and often' meal plan to support adoption of the PROMED intervention. The daily energy and protein requirements of each participant will be calculated based on National Institute of Health \& Care Excellence guidance for Nutrition Support in Adults at Risk of Malnutrition. Several resources have been developed to facilitate behaviour change: a) A PROMED Diet Information Booklet to include an overview of the PROMED Diet, tips for incorporating more PROMED foods into the diet and information on the health benefits of a PROMED diet, b) A PROMED Recipe Book offering ideas for breakfast, lunch and dinner as well as suitable snack ideas and c) key PROMED foods ordered through a local supermarket's online delivery service and delivered to participants' homes on a weekly or fortnightly basis for the 3-month active intervention phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention
Description: Participants will receive a dietary intervention identical to PROMED participants, plus an exercise intervention. The home-based exercises are based on a modified version of the 'ExWell@home' programme developed by health professionals with significant expertise in community-based exercise rehabilitation for chronic disease. Cardiorespiratory fitness will be determined using a 3-minute step test and pulse rate. Participants will receive access to pre-recorded exercise classes and a written resource designed for older adults (ExWell@home) and adapted for the current study. Participants will be encouraged to complete two sessions per week (30-60 minutes per session). To cater for differing abilities, four levels of classes will be available for participants: Chair based, basic, standard and advanced.
Study: NCT04781023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colpofix
Description: Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
Study: NCT06157359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scalp nerve block
Description: In the SNB group, bilateral scalp nerve blocks will performed using 20 mL of 0.75% ropivacaine after anesthesia induction. To cover the area of surgical incision and skull clamp, seven scalp nerves including the supratrochlear, supraorbital, zygomaticotemporal, auriculotemporal, lesser occipital and greater occipital nerves, are blocked bilaterally by injecting 1-2 ml of the solution using a 25-gauge needle.
Study: NCT05814289

Intervention type: OTHER
Group type: OTHER
Intervention: To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
Description: To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
Study: NCT01296217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph nod detection
Study: NCT05085730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InMode Morpheus8 System
Description: The InMode Morpheus8 System is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis and neoelastogenesis.
Study: NCT04254861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simplified Papilla Preservation Flap (SPPF) and PRGF ENDORET (PRGF ENDORET®-KMU16)
Description: A simplified papilla preservation flap (SPPF) will be performed. The clot phase of PRGF ENDORET (F2) will be placed in the defect, while the fibrin membrane phase (F1) will cover it.~Blood will be extracted and collected in dedicated tubes and then centrifuged. Up to 8 tubes of 9ml will be extracted. The time from the start of the extraction to the start of the centrifugation of the tubes must not exceed 4mins.~After centrifugation, the blood is separated into three components: Plasma rich in growth factors, White cells or leukocytes, red blood cells: this is the red column occupying the bottom of the tube.~Following BTI's instructions, fractioning of the centrifuged blood will be performed in order to separate Fraction 2 (F2), which contains a greater number of platelets and growth factors and will be used as a clot inside the periodontal defect from Fraction 1 (F1), which will be used as a fibrin member to cover the clot. The flaps will be repositioned and sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simplified Papilla Preservation Flap (SPPF) and GTR
Description: A simplified papilla preservation flap (SPPF) will be performed. The defect will then be treated according to the guided tissue regeneration (GTR) principle (control group). A deproteinized bovine bone mineral (DBBM) graft will be placed in the defect and covered by a collagen membrane.
Study: NCT04334057

Intervention type: DRUG
Intervention: Turoctocog alfa pegol
Description: Patients will be treated with commercially available Esperoct® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study: NCT06085378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urinary Kallidinogenase for injection
Description: The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.
Study: NCT01685034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergy immunotherapy (allergy shots)
Study: NCT05517408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol
Description: The first patient received Ciprofol 0.3mg/kg (actual body weight) at a rate of 1 mg/s. If the desired depth of sedation/anesthesia reached, then it was judged as negative, and the dose of Ciprofol in next patient would be decreased by one concentration gradient (the difference between two adjacent drugs was 1:1.1); If the desired sedation/anesthesia depth was not achieved, then it was judged as positive. And the dose of Ciprofol in next patient would be increased by one concentration gradient. Patients were enrolled consecutively until the trial was terminated at the eighth crossing point (positive to negative or negative to positive).
Study: NCT06308224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified-Otago Exercises
Description: Walking for 15 minutes before or after the strengthening and balance exercises of Modified-Otago.~Strengthening exercises for 10 minutes: Knee extensor, Knee flexor, Hip adductor, Ankle plantar flexors (calf raises), and Ankle dorsiflexion (toe raises).~Balance exercises 20 minutes: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel-toe stand), Tandem walk (heel-toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backward, sit to stand and Stair walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai-Chi Exercises
Description: Warm-up exercises for 10 minutes.~Tai Chi Qigong Exercises for 30 minutes: Commencing form and regulating breathing, Expanding your chest, Painting a rainbow, Circling arms to separate the clouds, Fixed step invert brachial, Row a boat in the middle of the lake, Shoulder the ball, Turning the body to look at the moon, Twisting waist and pushing palms, Horse step and cloud hands, Drag the sea and watch the sky, Undulating waves, Dove spreading wings, Extend arms and punch, Wild goose flying, Flywheel turning, Bounce ball while stepping, Pressing palms in calmness.~Cool-down exercises for 5 minutes.
Study: NCT04944420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health enSuite Caregivers
Description: Advice within Health enSuite Caregivers is organized into 5 priority areas: Taking Care of Yourself (Self-care), Support for You (Support), Supporting the Person Living with Dementia (Characteristics of Persons Living with Dementia), Communication, and Time Management.~Under My Priority Areas, participants will see these in order from highest to lowest need, based on their answers to the needs assessment. Each priority area contains small subtopics and specific tips for things to Try or Avoid. Navigation through the priority areas is user directed and at the participant's discretion. The goal is to make the information they need easy to access.
Study: NCT05456269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisantrene Dihydrochloride (high dose)
Description: Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisantrene Dihydrochloride (low dose)
Description: IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine Hydrochloride
Description: Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and cedazuridine
Description: PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
Study: NCT05899985

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System
Description: FerroTrace will be injected peri-tumorally during the surgeons staging endoscopy, with an MRI conducted 12h to 28 days after injection. The MRI will be blinded to the clinical team and will assess the location of the primary draining lymph nodes (sentinel lymph nodes or SLNs).~Patients will proceed to standard of care neoadjuvant therapy and/or surgery. During surgery, indocyanine green (ICG) will be used to identify draining lymph nodes. Following surgery, pathologists will use FerroMag to identify SLNs which will undergo standard H\&E assessment, and if negative ultras-staging (fine serial slice and immunochemistry).
Study: NCT05372094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Hearing Aid
Description: Commercially available hearing aid with various noise reduction strengths